ASIPP enews

ASIPP® ANNUAL MEETING 2020 RESCHEDULED.

SEPTEMBER 4-6. REGISTRATION NOW OPEN !

| REGISTRATION | PROSPECTUS | EXHIBITOR REGISTRATION |

THURSDAY | APRIL 16, 2020

UPCOMING WEBINAR

FRIDAY, APRIL 17, 2020 | 3:00PM - 5:00PM CDT

CPPR Webinar

Comprehensive Physician and Practice Resuscitation Training

3:00pm – 3:05pm

WEBINAR INTRODUCTION

3:05pm – 3:20pm

Dr. Devi interviews Kevin Pho on Evolving Role of Online Platforms during Pandemic – Kevin Pho, MD

3:20pm – 3:35pm

Overview of CPPR –

Laxmaiah Manchikanti, MD

3:35pm – 3:45pm

Financial Overview – Amol Soin, MD

3:45pm – 4:00pm

Ask CMS - Emily Yoder

Centers for Medicare and Medicaid Services

4:00pm – 4:15pm

Testing for Coronavirus and Antibodies: Value and Validity – Amit Mahajan, MD

3:00pm – 3:05pm

Insurance Issues; Business and Professional During and After Corona Pandemic.

Thomas Wierzbowski , Willow Risk Advisors

Christina Cassady ,Regional Manager, Risk Management, NORCAL Group

Nichole M. Pieters, MS, RN, CEN, CPHQ,

Senior Quality & Risk Management Specialist, NORCAL Group

4:30pm – 5:00pm

Open Forum Discussion Panel Panelists:

Devi Nampiaparampil, MD, Laxmaiah Manchikanti, MD, Amol Soin, MD, Amit Mahajan, MD, Christina Cassady, Nichole M. Pieters, MS, RN, CEN, CPHQ, Thomas Wierzbowski

Coronavirus destroys lungs. But doctors are finding its damage in kidneys, hearts and elsewhere

Coronavirus destroys lungs. But doctors are finding its damage in kidneys, hearts and elsewhere.

The new coronavirus kills by inflaming and clogging the tiny air sacs in the lungs, choking off the body’s oxygen supply until it shuts down the organs essential for life.

But clinicians around the world are seeing evidence that suggests the virus also may be causing heart inflammation, acute kidney disease, neurological malfunction, blood clots, intestinal damage and liver problems. That development has complicated treatment for the most severe cases of covid-19, the illness caused by the virus, and makes the course of recovery less certain, they said.

READ MORE | WASHINGTON POST |

Dr. Devi Nampiaparampil Pens Book

Hospitals and healthcare workers struggle to keep up with the demand as the new coronavirus (COVID-19) spreads across the U.S. and throughout the world.

Hundreds of millions of people are social distancing, quarantining, and sheltering in place to slow down the spread of the virus. The stock market is plunging and the global economy is heading into a recession because of the virus and because of the measures we are enforcing to stop it. Schools are closed. Restaurants, bars, and gyms are closed in many areas of the country. Major sports events, concerts and shows have been cancelled. Perhaps our greatest asset in this fight against the new coronavirus-- healthcare workers-- are becoming infected on the front lines. In the midst of this crisis, Doctor Devi explains what you need to know in a concise and easy-to-understand Question and Answer format.

Dr. Devi Nampiaparampil, a Harvard-trained doctor and a professor at NYU School of Medicine, breaks down the issues in this clear and compassionate handbook. What makes this virus so dangerous? How can I protect myself and my family? How did this happen?

For the latest guidelines, please always check:

TO ORDER THE BOOK GO TO | coronavirus-made-simple.com |

Pain Physician March/April

2020 Articles Available Online Now

The March/April issue of Pain Physician features

Evolutionary Therapeutic Strategies

Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCS) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use

Sairam Atluri, MD, Laxmaiah Manchikanti, MD, and Joshua A. Hirsch, MD

Position Statement

Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of the American Society of Interventional Pain Physicians (ASIPP)

Laxmaiah Manchikanti, MD, Christopher J. Centeno, MD, Sairam Atluri, MD, Sheri L. Albers, DO, Shane Shapiro, MD, Gerard A. Malanga, MD, Alaa Abd-Elsayed, MD, MPH, Mairin Jerome, MD, Joshua A. Hirsch, MD, Alan D. Kaye, MD, PhD, Steve M. Aydin, DO, Douglas Beall, MD, Don Buford, MD, Joanne Borg-Stein, MD, Ricardo Buenaventura, MD, Joseph A. Cabaret, MD, Aaron K. Calodney, MD, Kenneth D. Candido, MD, Cameron Cartier, MD, Richard Latchaw, MD, Sudhir Diwan, MD, Ehren Dodson, PhD, Zachary Fausel, MD, Michael Fredericson, MD, Christopher G. Gharibo, MD, Myank Gupta, MD, Adam M. Kaye, PharmD, FASCP, FCPhA, Nebojsa Nick Knezevic, MD, PhD, Radomir Kosanovic, MD, Matthew Lucas, DO, Maanasa V. Manchikanti , R. Amadeus Mason, MD, Kenneth Mautner, MD, Samuel Murala, MD, Annu Navani, MD, Vidyasagar Pampati, MSc, Sarah Pastoriza, DO, Ramarao Pasupuleti, MD, Cyril Philip, MD, Mahendra Sanapati, MD, Theodore Sand, PhD, Rinoo Shah, MD, Amol Soin, MD, Ian Stemper, MS, Bradley W. Wargo, DO, and Philippe Hernigou, MD

Health Policy Review

An Updated Analysis of Utilization of Epidural Procedures in Managing Chronic Pain in the Medicare Population from 2000 to 2018

Laxmaiah Manchikanti, MD, Mahendra R. Sanapati, MD, Amol Soin, MD, Maanasa V. Manchikanti, BS, Vidyasagar Pampati, MSc, Vanila Singh, MD, and Joshua A. Hirsch, MD

Update of Utilization Patterns of Facet Joint Interventions in Managing Spinal Pain from 2000 to 2018 in the US Fee-for-Service Medicare Population

Laxmaiah Manchikanti, MD, Mahendra R. Sanapati, MD, Vidyasagar Pampati, MSc, Amol Soin, MD, Sairam Atluri, MD, Alan D. Kaye, MD, PhD, Joysree Subramanian, MD, and Joshua A. Hirsch, MD

Survey

Interventional Pain Medicine Practice in the UK and the USA: A Survey of 242 Pain Physicians

Sanjeeva Gupta, MD, and Manohar Sharma, MD

FULL ARTICLE PDFs | painphysicianjournal.com |

Push Needed for At-Home Coronavirus Antibody Testing

An opportunity for the U.S. to catch up

Now 12 weeks after the first case on United States soil of COVID-19 on Jan. 21, 2020, access to testing remains a challenge. South Korea and the United States reported their first cases on the same day; 6 weeks later, testing in South Korea was 1,900 per million residents versus 6 per million in the U.S . The result has been two-fold: individuals with COVID-19 are unknowingly transmitting infection to others and public health efforts at mitigation have been hampered by lack of reliable data.

Up until now testing for COVID-19 in the U.S. has largely relied on PCR assays of nasal swab collections by healthcare professionals. Scale-up efforts have been hampered by lack of testing capacity, as well as a shortage of nasal swab test kits. There is now a second option for testing: an antibody-based serology test that can be done with a pinprick blood test with results available at the point-of-care in 10-15 minutes. The antibody test can be used as a diagnostic for active infection (IgM antibodies), similar to a PCR test, and in addition, for assessing immunity from prior infection (IgG antibodies). This means antibody tests could be used to survey a population to determine cumulative infection and to allow certain individuals to return to work and partially lift stay-at-home orders.